Hybio Pharmaceutical Co., Ltd.
300199
Kedudukan dalam Saham
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Harga Saham
$3.69
Modal Pasaran
$3.11B
Perubahan (1 hari)
-7.75%
Perubahan (1 tahun)
21.56%
Negara
CN
Perdagangan Hybio Pharmaceutical Co., Ltd. (300199)
Kategori
Healthcare
Nisbah P/E bagi Hybio Pharmaceutical Co., Ltd. (300199)
Nisbah P/E pada October 2026 TTM: 178.55
Menurut laporan kewangan dan harga saham terkini Hybio Pharmaceutical Co., Ltd., nisbah P/E semasa (TTM) ialah 178.55. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -64.45.
Sejarah nisbah P/E bagi Hybio Pharmaceutical Co., Ltd. dari 2007 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 178.55 | -60.10% |
| 2025 | 447.50 | -794.34% |
| 2024 | -64.45 | 178.13% |
| 2023 | -23.17 | -44.70% |
| 2022 | -41.90 | -111.59% |
| 2021 | 361.52 | -3,851.08% |
| 2020 | -9.64 | 66.46% |
| 2019 | -5.79 | -75.73% |
| 2018 | -23.86 | -151.68% |
| 2017 | 46.17 | -15.27% |
| 2016 | 54.48 | -24.79% |
| 2015 | 72.44 | 1.95% |
| 2014 | 71.05 | 7.25% |
| 2013 | 66.25 | 111.39% |
| 2012 | 31.34 | -28.70% |
| 2011 | 43.95 | 5.01% |
| 2010 | 41.86 | -31.43% |
| 2009 | 61.04 | -29.17% |
| 2008 | 86.18 | -23.30% |
| 2007 | 112.35 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 23.30 | -86.95% |
DE
|
|
| 26.92 | -84.92% |
DE
|
|
| 55.58 | -68.87% |
JP
|
|
| 61.13 | -65.76% |
CH
|
|
| 34.87 | -80.47% |
IN
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.